Outlook Therapeutics, Inc.
OTLKNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — | — |
| Operating income | −$67.1M | −$71.7M | −$53.1M | −$63.1M | −$51.7M | −$36.8M |
| Net income | −$62.4M | −$75.4M | −$59.0M | −$66.1M | −$53.2M | −$35.2M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M | $19.7M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M | $16.9M |
| Equity | −$32.2M | −$73.1M | −$14.4M | $8.7M | $4.6M | $2.8M |
| EPS (diluted) | $-1.79 | $-4.06 | $-4.72 | $-0.31 | $-0.35 | $-0.67 |
| Shares out. | 64.1M | 24.9M | 260.3M | 228.2M | 224.3M | 127.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −4744.3%
- Net margin
- −4416.2%
- Return on equity
- 193.9%
- Return on assets
- −335.9%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 273.2%
- Debt / equity
- —
- Book value / share
- $-0.50
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -141.20distress
- Accruals / assets
- −57.0%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Gms Ventures & InvestmentsActivist (13D)Jun 1, 2026
- Intracoastal Capital, LlcPassive (13G)Apr 24, 2026
- Sphera Funds Management Ltd.Passive (13G)Feb 5, 2026
- Empery Asset Management, LpPassive (13G)Oct 21, 2025
- Tang Capital Management LlcPassive (13G)Aug 14, 2025
- Great Point Partners LlcPassive (13G)Aug 14, 2025
- Tang Capital Partners LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Sukhtian Ghiath M.Director | May 28, 2026 | Buy | 8.5M | $0.59 |
| Sukhtian Faisal GhiathDirector | May 27, 2026 | Buy | 122,174 | $0.41 |
| Haddadin Yezan MuntherDirector | May 26, 2026 | Buy | 34,000 | $0.44 |
| Thurman Randy HDirector | May 26, 2026 | Buy | 5,000 | $0.43 |
| Hilzinger Kurt JDirector | May 26, 2026 | Buy | 400,000 | $0.44 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.1M | 2.2 | +41.3% |
| Apr 30, 2026 | 6.4M | 1.2 | +37.3% |
| Apr 15, 2026 | 4.7M | 1.0 | +47.3% |
| Mar 31, 2026 | 3.2M | 1.0 | -0.0% |
| Mar 13, 2026 | 3.2M | 3.0 | -13.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Other material eventMay 29, 2026
- Other material eventMay 28, 2026
- Other material eventMay 26, 2026
- Results of operationsMay 18, 2026
- Entered a material agreement · Terminated a material agreement · Results of operationsMay 13, 2026
- Unregistered equity sale · Other material eventApr 23, 2026
- Other material eventApr 21, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13D/AJun 1, 2026
- 4Jun 1, 2026
- DEFA14AJun 1, 2026
- DEF 14AJun 1, 2026
- 8-KFORM 8-KJun 1, 2026
- 8-KFORM 8-KMay 29, 2026
- 424B5May 29, 2026
- 8-KFORM 8-KMay 28, 2026
- 4PRIMARY DOCUMENTMay 27, 2026
- 4PRIMARY DOCUMENTMay 27, 2026
- 4PRIMARY DOCUMENTMay 27, 2026
- 4PRIMARY DOCUMENTMay 27, 2026
- 8-KFORM 8-KMay 26, 2026
- PRE 14AMay 22, 2026
- 8-KFORM 8-KMay 18, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.